Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

@article{Misale2014ResistanceTA,
  title={Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.},
  author={Sandra Misale and Federica Di Nicolantonio and Andrea Sartore-Bianchi and Salvatore Siena and Alberto Bardelli},
  journal={Cancer discovery},
  year={2014},
  volume={4 11},
  pages={1269-80}
}
UNLABELLED The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and MET drive primary (de novo) resistance to anti-EGFR treatment. Recently, the emergence of alterations in the same genes was detected in patients who responded to EGFR blockade and then relapsed. These results illuminate a striking overlap between genes that, when mutated, drive primary and secondary resistance to anti… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS